Monographie - Alprostadil

Ultimo aggiornamento :
27/11/2024

Alprostadil

Struttura chimica

Nome commerciale

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Alfaprostin	Egitto
Alistint	Perù
Alpros	Turchia
Alprostadil	Argentina, Canada, Chile, Ecuador, Germania, Malaysia, Perù, Romania, Spagna, Stati Uniti d’America, Turchia
Alprostapint	Argentina, Austria, Colombia, Ecuador, Perù, Ungheria
Alprostar	Italia
Aplicav	Brasile
Cardiobon	Argentina, Perù
Caverject	Africa del Sud, Austria, Belgio, Brasile, Canada, Danimarca, Francia, Gran Bretagna, Italia, Norvegia, Polonia, Portogallo, Slovenia, Spagna, Stati Uniti d’America, Svezia, Svizzera, Turchia
Edex	Francia
Liple	Giappone
Minprog	Austria, Germania
Ostapint	Messico, Perù
Palux	Giappone
Pridax	Austria, Germania, Romania, Spagna
Prolisina VR	Argentina
Prostandin	Giappone
Prostavasin	Austria, Egitto, Germania, Iran, Italia, Lussemburgo, Polonia, Ungheria
Prostin VR	Arabia Saudita, Australia, Belgio, Canada, Danimarca, Finlandia, Gran Bretagna, Grecia, Iran, Italia, Lussemburgo, Malaysia, Norvegia, Paesi Bassi, Polonia, Portogallo, Stati Uniti d’America, Svizzera, Ungheria, Venezuela
Prostine VR	Francia
Vasaprostan	Romania

Bibliografia : Alprostadil

	tipo	pubblicazione
1072	Rivista	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1899	Rivista	Trissel LA, Zhang Y. Long-term stability of Trimix : a three drug injection used to treat rectile dysfunction. Int J Pharm Compound 2004 ; 8, 3: 231-235.
2003	Rivista	Paul M, Razzouq N, Tixier G, Astier A. Stability of prostaglandin E1 (PGE1) in aqueous solutions. EJHP Science 2005 ; 2: 31-36.
2090	Rivista	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2150	Rivista	Soli M, Bertaccini A, carparelli F, Gotti R, Cavrini V, Andrisano V, Martorana G. Vasoactive cocktails for erectile dysfunction: chemical stability of PGE1, papaverine and phentolamine. J Urology 1998 ; 160; 2: 551-555.
2151	Rivista	Gatti R, Gotti R, Cavrini V, Soli M, Bertaccini A, Carparelli F. Stability study of prostaglandin E1 (PGE1) in physiological solutions by liquid chromatography (HPLC). Int J Pharm 1995 ; 115: 113-117.
3201	Rivista	Dice JE. Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit. J Pediatr Pharmacol Ther 2006 ; 11:233?6.
3448	Rivista	Vieillard V, Eychenne N, Astier A, Yiou R, Deffaux C, Paul M. Physicochemical stability study of a new Trimix formulation for treatment of erectile dysfunction. Ann Pharm Fr 2013 ; 71, 5: 358-363.
3761	Libro	Chavan E. Etude de la stabilité de solutions de prostaglandine E1 à 48 et 72 heures en vue d'une administration parentérale en continu à des patients de néonatalogie. Master en pharmacie - University of Geneva 2014
3961	Rivista	McCluskey S.V,Kirkham K,Munson J.M. Stability of Alprostadil in 0.9% Sodium Chloride Stored in Polyvinyl Chloride Containers. Int J Pharm Compound 2017 ; 21, 2: 150-153.
4069	Rivista	Palmero D, Chavan E, Berger-Gryllaki M, Tolsa J-F, Di Paolo E, Pannatier A, Henry H, Sadeghipour F. Stability of prostaglandin E1 solutions stored in polypropylene syringes for continuous intravenous administration to newborns. EJHP 2018 ; 25, e2
4389	Rivista	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4491	Rivista	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2020
4507	Rivista	Ross E, Salinas A, Petty K, Her C, Carpenter J. Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing. Am J Health-Syst Pharm 2020 ;77,23:1980-1985
4543	Rivista	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295.
4570	Rivista	Greenhill K, Hornsby E, Gorman G. Investigations of Physical Compatibilities of Commonly Used Intravenous Medications with and without Parenteral Nutrition in Pediatric Cardiovascular Intensive Care Unit Patients. Pharmaceuticals 2019
4651	Rivista	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2021 ;180,1169–1176.
4837	Rivista	De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page‑Sharp N, Moore B.R, Batty K.T. Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings. Eur J Clin Pharmacol 2024 ; 80:1079–1087.

Mentions Légales